UNION therapeutics to present at the 6th Annual Dermatology Drug Development Summit
- Data on pharmacological properties of orismilast to be presented on 2nd of November 2022
- Orismilast is a potent next-generation PDE4 inhibitor with broad anti-inflammatory properties in development as a first-in-class or best-in-class treatment for psoriasis, atopic dermatitis (AD) and hidradenitis suppurativa (HS)
Hellerup, Denmark, 25 October 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, today announced that data on the pharmacological properties of orismilast will be presented at the 6th Annual Dermatology Drug Development Summit at 1-3 November 2022 in Boston, MA, US.
Dermatology Drug Development Summit
Presentation: Overcoming the moderate efficacy conundrum in PDE4 inhibition through hidradenitis suppurativa
Presenter: Kim D. Kjøller, CEO, UNION
Session date and time: Wednesday 2. November 2022 at 11:30am EST.
Kim Kjøller, CEO, will also participate in a panel discussion “Exploring the Dermatology Financing Landscape for 2022 and Beyond” on 1. November at 8:00am EST.
About orismilast
UNION is developing orismilast, which is a next-generation PDE4 inhibitor with high potency for the PDE4 subtypes linked to inflammation. It operates early in the inflammation cascade to induce a broad range of anti-inflammatory effects. Orismilast has the potential to inhibit many inflammatory pathways involved in dermatological and immunological diseases and holds potential to become a safe and efficacious treatment option in various dermatological and immunological diseases.
UNION is currently developing orismilast MR tablet for the treatment of psoriasis, AD and HS. UNION is progressing orismilast as a MR tablet to reduce the occurrence of gastrointestinal side effects typically associated with PDE4 inhibition.
In November 2020, the FDA cleared UNION’s Investigational New Drug (IND) application for orismilast MR tablet, and, in November 2021, the FDA granted Fast Track designation to orismilast MR tablet for the treatment of moderate to severe AD. Moreover, in September 2021, UNION entered into a strategic partnership and licensing agreement with Innovent Biologic for orismilast in Mainland China, Hong Kong, Macau and Taiwan.
Contacts
Morten Boesen, Chief Financial Officer, UNION therapeutics A/S
+45 2381 5487
morten.boesen@uniontherapeutics.com
Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S
+45 5385 3044
About UNION therapeutics
UNION therapeutics is a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases. The company is currently working with two complementary chemistry classes, spanning immunology and microbiology with multiple candidates in clinical development. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at www.uniontherapeutics.com